About ImmuneBridge
ImmuneBridge is a private company based in San Francisco, California, incorporated in 2022 in Delaware. It has reported $15,782,000 raised in two offerings on Form D since January 2023. Its chief executive is Stuart Jacobson.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 24, 2025 | Apr 2, 2025 | $5,632,000of $7.1M target | 6 | $938K | EquityRule 506(b) | Form D ↗ |
| Dec 27, 2022 | Jan 10, 2023 | $10,150,000of $14.1M target | 15 | $676K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $15,782,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ImmuneBridge's Form D filed Apr 2, 2025.
DM
Dylan Morris
Director
Also a board member at Averna Therapeutics, a director at Gameto and a managing director at insight partners at Superluminal Medicines.
NI
Nadiya Ishnazarova
Director
OD
Omri Amirav-Drory
Director
AJ
Alicia Jackson
Director
SJ
Stuart Jacobson
President and CEO, director
TF
Thomas Farrell
Director
Earlier filings also listed Peretz Partensky (president and director, last listed Jan 2023), Mary Warren (director, last listed Jan 2023), Gregory Bonfiglio (director, last listed Jan 2023) and Cheryl Zimberlin (director, last listed Jan 2023).